Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
107 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Burns - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Burns - Pipeline Review, H1 2016', provides an overview of the Burns pipeline landscape. The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Burns - The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Burns therapeutics and enlists all their major and minor projects - The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Burns Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Burns - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Burns Overview 10 Therapeutics Development 11 Pipeline Products for Burns - Overview 11 Pipeline Products for Burns - Comparative Analysis 12 Burns - Therapeutics under Development by Companies 13 Burns - Therapeutics under Investigation by Universities/Institutes 15 Burns - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Burns - Products under Development by Companies 20 Burns - Products under Investigation by Universities/Institutes 22 Burns - Companies Involved in Therapeutics Development 23 Adocia 23 AlgiPharma AS 24 Amarantus Bioscience Holdings, Inc. 25 American Gene Technologies International Inc. 26 Biogenomics Limited 27 CytoTools AG 28 Destiny Pharma Limited 29 HanAll Biopharma Co., Ltd. 30 Kuros Biosciences AG 31 Madam Therapeutics B.V. 32 MediWound Ltd. 33 Novartis AG 34 Phosphagenics Limited 35 Se-cure Pharmaceuticals Ltd. 36 Stratatech Corporation 37 USV Limited 38 Burns - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Combination Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 A-3APO - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AG-110 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 albumin (human) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ALLO-ASC - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Biochaperone PDGF-BB - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 bromelains - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BVS-857 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Cell Therapy for Dermatology and Immunology - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 epidermal growth factor biosimilar - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Gene Therapy for Burns - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 HL-156FIB - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 IMSP-001 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 KUR-212 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 lidocaine hydrochloride - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Monoclonal Antibody Conjugate to Target TNF-alpha for Burns and Wounds - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 MP-101 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Neu-2000 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Nu-2 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Oligomer G for Wounds And Burns - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 P-12 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 P-148 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 PEP-04 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 SC-106 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 silver sulfadiazine - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules for Burn - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 XF-70 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Burns - Recent Pipeline Updates 86 Burns - Dormant Projects 90 Burns - Discontinued Products 93 Burns - Product Development Milestones 94 Featured News & Press Releases 94 Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized 94 Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS) 95 Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters 95 Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania 96 Oct 20, 2015: Argentina's Ministry of Health Approves MediWound's NexoBrid 97 Sep 30, 2015: MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S. 98 Sep 29, 2015: MediWound Reports Highlights From the European Burns Association Congress 99 Sep 10, 2015: MediWound's NexoBrid Highlighted at the 16th European Burns Association Congress 100 Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting 104 Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting 105 Appendix 106 Methodology 106 Coverage 106 Secondary Research 106 Primary Research 106 Expert Panel Validation 106 Contact Us 106 Disclaimer 107
List of Tables
Number of Products under Development for Burns, H1 2016 11 Number of Products under Development for Burns - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Comparative Analysis by Unknown Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Burns - Pipeline by Adocia, H1 2016 23 Burns - Pipeline by AlgiPharma AS, H1 2016 24 Burns - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 25 Burns - Pipeline by American Gene Technologies International Inc., H1 2016 26 Burns - Pipeline by Biogenomics Limited, H1 2016 27 Burns - Pipeline by CytoTools AG, H1 2016 28 Burns - Pipeline by Destiny Pharma Limited, H1 2016 29 Burns - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 30 Burns - Pipeline by Kuros Biosciences AG, H1 2016 31 Burns - Pipeline by Madam Therapeutics B.V., H1 2016 32 Burns - Pipeline by MediWound Ltd., H1 2016 33 Burns - Pipeline by Novartis AG, H1 2016 34 Burns - Pipeline by Phosphagenics Limited, H1 2016 35 Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H1 2016 36 Burns - Pipeline by Stratatech Corporation, H1 2016 37 Burns - Pipeline by USV Limited, H1 2016 38 Assessment by Monotherapy Products, H1 2016 39 Assessment by Combination Products, H1 2016 40 Number of Products by Stage and Target, H1 2016 42 Number of Products by Stage and Mechanism of Action, H1 2016 44 Number of Products by Stage and Route of Administration, H1 2016 46 Number of Products by Stage and Molecule Type, H1 2016 48 Burns Therapeutics - Recent Pipeline Updates, H1 2016 86 Burns - Dormant Projects, H1 2016 90 Burns - Dormant Projects (Contd..1), H1 2016 91 Burns - Dormant Projects (Contd..2), H1 2016 92 Burns - Discontinued Products, H1 2016 93
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
